NCT00560716View on ClinicalTrials.gov

A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

November 30, 2009

Conditions
Solid Tumors
Interventions
DRUG

CYC116

Dose escalation of CYC116

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

78229

South Texas Accelerated Research Therapeutics, San Antonio

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT00560716 - A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter